Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension

被引：0
|
作者：
Thaci, Diamant [1 ]
Puig, Luis [2 ]
Merola, Joseph F. [3 ]
Jullien, Denis [4 ]
Costanzo, Antonio [5 ]
Wang, Maggie [6 ]
Deherder, Delphine [7 ]
Lopez Pinto, Jose M. [8 ]
Lebwohl, Mark [9 ]
机构：
[1] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Schleswig Holst, Germany
[2] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
[3] UT Southwestern Med Ctr, Dallas, TX USA
[4] Univ Lyon, Hosp Civils Lyon, Dept Dermatol, Hop Edouard Herriot, Lyon, France
[5] IRCCS, Dept Dermatol, Humanitas Clin & Res Ctr, Milan, Italy
[6] UCB Pharma, Morrisville, NC USA
[7] UCB Pharma, Braine Lalleud, Belgium
[8] UCB Pharma, Madrid, Spain
[9] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2348
引用
收藏
页码：4733 / 4735
页数：3
相关论文
共 50 条
  • [1] Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension
    Sinclair, Rodney
    Thaci, Diamant
    Vender, Ronald
    de Rie, Menno
    Conrad, Curdin
    Soung, Jennifer
    Strober, Bruce
    Wang, Maggie
    Cross, Nancy
    Deherder, Delphine
    Gomez, Natalie Nunez
    Gottlieb, Alice B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 18 - 18
  • [2] Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period
    Warren, Richard B.
    Lebwohl, Mark
    Thaci, Diamant
    Gooderham, Melinda
    Pinter, Andreas
    Paul, Carle
    Gisondi, Paolo
    Szilagyi, Balint
    White, Katy
    Deherder, Delphine
    Staelens, Fabienne
    Lambert, Jeremy
    Strober, Bruce
    BRITISH JOURNAL OF DERMATOLOGY, 2025,
  • [3] Safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis: Long-term results from BE SURE randomised controlled trial and BE BRIGHT open-label extension
    Thaci, Diamant
    Vender, Ronald
    de Rie, Menno
    Conrad, Curdin
    Pariser, David
    Strober, Bruce
    Vanvoorden, Veerle
    Peterson, Luke
    Madden, Cynthia
    De Cuyper, Dirk
    Rubel, Diana
    Kimball, Alexa
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 14 - 15
  • [4] Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
    Valenzuela, F.
    Korman, N. J.
    Bissonnette, R.
    Bakos, N.
    Tsai, T. -F.
    Harper, M. K.
    Ports, W. C.
    Tan, H.
    Tallman, A.
    Valdez, H.
    Gardner, A. C.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 853 - 862
  • [5] Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
    Kim A. Papp
    Saskia de Vente
    Jiewei Zeng
    Mary Flack
    Byron Padilla
    Stephen K. Tyring
    Dermatology and Therapy, 2021, 11 : 487 - 497
  • [6] Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
    Papp, Kim A.
    de Vente, Saskia
    Zeng, Jiewei
    Flack, Mary
    Padilla, Byron
    Tyring, Stephen K.
    DERMATOLOGY AND THERAPY, 2021, 11 (02) : 487 - 497
  • [7] Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Elewski, Boni
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Staelens, Fabienne
    Spelman, Lynda
    Eyerich, Kilian
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 14 - 14
  • [8] Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial
    Strober, Bruce
    Tada, Yayoi
    Mrowietz, Ulrich
    Lebwohl, Mark
    Foley, Peter
    Langley, Richard G.
    Warren, Richard B.
    Wang, Maggie
    Vanvoorden, Veerle
    Szilagyi, Balint
    Ciaravino, Valerie
    Paul, Carle
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (06) : 749 - 759
  • [9] A long-term, open-label study of the safety and efficacy of oral tazarotene in moderate to very severe plaque psoriasis
    Menter, A
    Lew-Kaya, D
    Beddingfield, F
    Walker, PS
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P2 - P2
  • [10] Bimekizumab efficacy and safety up to two years in patients with moderate to severe plaque psoriasis switching from ustekinumab: Results from the interim BE BRIGHT open-label extension trial
    Leonardi, Craig
    Sator, Paul
    Morita, Akimichi
    Kokolakis, Georgios
    Blauvelt, Andrew
    Warren, Richard
    De Cuyper, Dirk
    Madden, Cynthia
    Vanvoorden, Veerle
    Wang, Maggie
    Foley, Peter
    Papp, Kim
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 13 - 14
12345